<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CROMOLYN SODIUM- cromolyn sodium solution/ drops </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<h1>
<span class="Bold">Cromolyn Sodium </span><br><span class="Bold">Ophthalmic Solution USP, 4%</span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01bf7208-c040-47ff-b845-87946b6a8bc5"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_dda1b957-0beb-4e96-8aa7-448db8e36ab1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Cromolyn sodium ophthalmic solution USP, 4% is a clear, colorless, sterile solution for topical ophthalmic use. </p>
<p>Cromolyn sodium is represented by the following structural formula:</p>
<div class="Figure">
<a name="id208"></a><img alt="cromolyn sodium (structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5d8ed6be-ecc9-4e26-b6c1-4eaef46c0fa7&amp;name=d31b4852-4c99-42e5-afe2-36f4cbb27167-01.jpg">
</div>
<p>C<span class="Sub">23</span>H<span class="Sub">14</span>Na<span class="Sub">2</span>O<span class="Sub">11</span>                                                                                                           Mol. Wt. 512.34</p>
<p>Chemical Name: Disodium 5,5'- [(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-carboxylate]</p>
<p>Pharmacologic Category: Mast cell stabilizer.</p>
<p><span class="Bold">EACH mL CONTAINS: </span>ACTIVE: Cromolyn Sodium 40 mg (4%); INACTIVES: Edetate Disodium 0.1% and Purified Water. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (4.0 - 7.0). PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f0a0ded4-2ee4-4b05-9999-fd443419bdaf"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First"><span class="Italics">In vitro </span>and <span class="Italics">in vivo </span>animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) from the mast cell.</p>
<p>Another activity demonstrated <span class="Italics">in vitro </span>is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.</p>
<p>Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity.</p>
<p>Cromolyn sodium is poorly absorbed. When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.</p>
<p>In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3c6fe95b-5a4c-4614-aea5-5dfc48ea6570"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Cromolyn sodium ophthalmic solution is indicated in the treatment of vernal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, vernal <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and vernal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_424d5971-67dd-4083-af60-89ceb393f2fc"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Cromolyn sodium ophthalmic solution is contraindicated in those patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to cromolyn sodium or to any of the other ingredients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d62b6ddc-f957-49a0-bf4b-760326069597"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_c883b6dc-7bad-4ee3-9b6f-af5149ddd084"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">Patients may experience a transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> following application of cromolyn sodium ophthalmic solution.</p>
<p>The recommended frequency of administration should not be exceeded (<span class="Bold">see <a href="#i4i_dosage_admin_id_8e39d841-f89c-4d2b-8e49-e99e04f5daa5">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_925fea8a-f5c8-4726-883e-87b78382739a"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients should be advised to follow the patient instructions listed on the Information for Patients sheet.</p>
<p>Users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, vernal <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, or vernal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. Do not wear contact lenses during treatment with cromolyn sodium ophthalmic solution.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_fca4c851-7693-4f22-999d-e8a8f7613e07"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility:</h2>
<p class="First">Long-term studies of cromolyn sodium in mice (12 months intraperitoneal administration at doses up to 150 mg/kg three days per week): hamsters (intraperitoneal administration at doses up to 52.6 mg/kg three days per week for 15 weeks followed by 17.5 mg/kg three days per week for 37 weeks), and rats (18 months subcutaneous administration at doses up to 75 mg/kg six days per week) showed no neoplastic effects. The average daily maximum dose levels administered in these studies were 192.9 mg/m<span class="Sup">2</span> for mice, 47.2 mg/m<span class="Sup">2</span> for hamsters and 385.8 mg/m<span class="Sup">2</span> for rats. These doses correspond to approximately 6.8, 1.7, and 14 times the maximum daily human dose of 28 mg/m<span class="Sup">2</span>.</p>
<p>Cromolyn sodium showed no mutagenic potential in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>/microsome plate assays, mitotic gene conversion in <span class="Italics">Saccharomyces cerevisiae </span>and in an <span class="Italics">in vitro </span>cytogenetic study in human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p>No evidence of impaired fertility was shown in laboratory reproduction studies conducted subcutaneously in rats at the highest doses tested, 175 mg/kg/day (1050 mg/m<span class="Sup">2</span>) in males and 100 mg/kg/day (600 mg/m<span class="Sup">2</span>) in females. These doses are approximately 37 and 21 times the maximum daily human dose, respectively, based on mg/m<span class="Sup">2</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a857d003-3c0d-42c9-9b56-817fe5d3216b"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy:</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_aa1dd267-1656-430e-848b-d2f59ac8d4f9"></a><a name="section-6.5"></a><p></p>
<h2>Teratogenic effects:</h2>
<p class="First"><span class="Bold">Pregnancy Category B. </span>Reproduction studies with cromolyn sodium administered subcutaneously to pregnant mice and rats at maximum daily doses of 540 mg/kg (1620 mg/m<span class="Sup">2</span>) and 164 mg/kg (984 mg/m<span class="Sup">2</span>), respectively, and intravenously to rabbits at a maximum daily dose of 485 mg/kg (5820 mg/m<span class="Sup">2</span>) produced no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformation</span>. These doses represent approximately 57, 35, and 205 times the maximum daily human dose, respectively, on a mg/m<span class="Sup">2</span> basis. Adverse fetal effects (increased resorption and decreased fetal weight) were noted only at the very high parenteral doses that produced maternal toxicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_05bc5b00-1979-4b63-9c4d-60c03341f809"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cromolyn sodium ophthalmic solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c36a24cc-ce11-41ca-8091-d16de540b906"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 4 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_b34648d7-f5be-420c-bb47-37079a06795f"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ed3471bc-282c-4edd-9e49-e5be4bc77cc6"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">The most frequently reported adverse reaction attributed to the use of cromolyn sodium ophthalmic solution, on the basis of reoccurrence following readministration, is transient <span class="product-label-link" type="condition" conceptid="4201702" conceptname="Sore eye">ocular stinging</span> or burning upon instillation.</p>
<p>The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributed to the drug:</p>
<p><span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">Conjunctival injection</span>; watery eyes; <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">itchy eyes</span>; dryness around the eye; puffy eyes; <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>; and <span class="product-label-link" type="condition" conceptid="380403" conceptname="External hordeolum">styes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> have been reported rarely and include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8e39d841-f89c-4d2b-8e49-e99e04f5daa5"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The dose is 1 – 2 drops in each eye 4 – 6 times a day at regular intervals.</p>
<p>One drop contains approximately 1.6 mg cromolyn sodium.</p>
<p>Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed.</p>
<p>Symptomatic response to therapy (decreased <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, tearing, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.</p>
<p>If required, corticosteroids may be used concomitantly with cromolyn sodium ophthalmic solution.</p>
<p><span class="Bold">FOR OPHTHALMIC USE ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c87f1f2d-e334-42ee-8aac-ee547cc0d18d"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Cromolyn sodium ophthalmic solution USP, 4% is supplied in a plastic bottle individually cartoned with a controlled drop tip in the following sizes:</p>
<p>10 mL bottle (NDC 24208-961-10) </p>
<p><span class="Bold"><span class="Underline">DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1eb80db2-c604-4b69-9d2a-b8a1d5bd194f"></a><a name="section-9.1"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store between 15°-25°C (59°-77°F). Protect from light – store in original carton. Keep tightly closed. Replace cap immediately after use.</p>
<p>KEEP OUT OF REACH OF CHILDREN.</p>
<p>Revised October 2014</p>
<p><span class="Bold">Bausch &amp; Lomb Incorporated</span><br>Tampa, Florida 33637<br>©Bausch &amp; Lomb Incorporated</p>
<p>9087001 (Folded)<br>9087101 (Flat)</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_9f99e6da-26f0-4478-a3e0-ebde2a9a283a"></a><a name="section-10"></a><p></p>
<h1>Patient Instructions</h1>
<p class="First"><span class="Bold"><span class="Underline">PHARMACIST — DETACH HERE AND GIVE INSTRUCTIONS TO PATIENTS</span></span></p>
<p><span class="Bold">Information for the Patient</span></p>
<p><span class="Bold">Cromolyn Sodium Ophthalmic Solution USP, 4% (</span>STERILE<span class="Bold">)</span></p>
<p>It is important to use Cromolyn sodium ophthalmic solutionUSP, 4% <span class="Bold">regularly</span>, as directed by your physician.</p>
<p>1. Thoroughly wash your hands.</p>
<p>2. Remove safety seal (Figure 1).</p>
<p>3. Remove cap (Figure 2).</p>
<p>4. Sit or stand comfortably, with your head tilted back (Figure 3).</p>
<p>5. Open eyes, look up, and draw the lower lid of your eye down gently with your index finger (Figure 4).</p>
<p>6. Hold the Cromolyn sodium ophthalmic solution USP, 4% bottle upside down. Place dropper tip as close as possible to the lower eyelid and gently squeeze out the prescribed number of drops (Figure 5).</p>
<p>7. Do not touch the eye or eyelid with the dropper tip.</p>
<p>8. Blink a few times to make sure the eye is covered with the solution.</p>
<p>9. Close your eye and remove any excess solution with a clean tissue.</p>
<p>10. Repeat process in the other eye.</p>
<p> </p>
<div class="Figure">
<a name="id447"></a><img alt="Patient Instructions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5d8ed6be-ecc9-4e26-b6c1-4eaef46c0fa7&amp;name=d31b4852-4c99-42e5-afe2-36f4cbb27167-02.jpg">
</div>
<p><span class="Bold">SPECIAL TIPS</span></p>
<p>1. Avoid placing Cromolyn sodium ophthalmic solution USP, 4% solution directly on the cornea (the area just over the pupil), because it is especially sensitive. You will find the administration of eye drops more comfortable if you place the drops just inside the lower eyelid, as shown in Figure 5 on the previous page.</p>
<p>2. To avoid contamination of the solution, do not touch dropper tip to the eye, fingers or any other surface. Replace cap after use. It is recommended that any remaining contents be discarded after the treatment period prescribed by your physician.</p>
<p>3. Store between 15°-25°C (59°-77°F). Protect from light – store in original carton. Keep tightly closed. Replace cap immediately after use.</p>
<p>4. Keep out of the reach of children.</p>
<p>5. Do not use with any other ocular medication unless directed by your physician. Do not wear contact lenses during treatment with Cromolyn sodium ophthalmic solution USP, 4%.</p>
<p><span class="Bold">Bausch &amp; Lomb Incorporated</span><br>Tampa, Florida 33637<br><br><span class="Sup">©</span> Bausch &amp; Lomb Incorporated.</p>
<p>9087001 (Folded)<br>9087101 (Flat)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2728a0b7-dce9-4ecc-89b4-3de9dc5865f6"></a><a name="section-11"></a><p></p>
<h1>Principal Display Panel – Cromolyn Carton Label -10mL</h1>
<div class="Figure">
<a name="id477"></a><img alt="Cromolyn Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5d8ed6be-ecc9-4e26-b6c1-4eaef46c0fa7&amp;name=d31b4852-4c99-42e5-afe2-36f4cbb27167-03.jpg">
</div>
<p class="First">NDC24208-961-10 </p>
<p>BAUSCH + LOMB</p>
<p><span class="Bold">Cromolyn Sodium</span><br><span class="Bold">Ophthalmic </span><br><span class="Bold">Solution USP, 4% </span></p>
<p><span class="Bold">(STERILE)</span></p>
<p><span class="Bold">Rx only </span></p>
<p><span class="Bold">10 mL</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_b53a92e2-4e60-4937-857f-a33924e7e261"></a><a name="section-12"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id-281804242"></a><img alt="CromolynLabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5d8ed6be-ecc9-4e26-b6c1-4eaef46c0fa7&amp;name=CromolynLabel.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CROMOLYN SODIUM 		
					</strong><br><span class="contentTableReg">cromolyn sodium solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-961</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CROMOLYN SODIUM</strong> (CROMOLYN) </td>
<td class="formItem">CROMOLYN SODIUM</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-961-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074443</td>
<td class="formItem">05/26/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-961)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7f7abf2d-7197-4c5a-a379-1cf98ba715ad</div>
<div>Set id: 5d8ed6be-ecc9-4e26-b6c1-4eaef46c0fa7</div>
<div>Version: 2</div>
<div>Effective Time: 20150120</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
